Boston Scientific keeps Penumbra deal on track as Penumbra stock costs EUR 284.00
Boston Scientific's planned acquisition of Penumbra remains on track for completion by year-end 2026, despite Penumbra reporting acquisition-related expenses and no full-year financial guidance. Penumbra's second-quarter revenue grew by 14.90 percent to USD 390.05 million, but diluted earnings per share missed consensus estimates. Penumbra stock was trading at EUR 284.00 at Lang & Schwarz.
Penumbra, Inc. (PEN) Stock forecasts
This article from Yahoo Finance is an empty placeholder page that was meant to display stock forecasts for Penumbra, Inc. (PEN). However, it indicates an error in data retrieval and contains no actual content regarding the stock. The page primarily consists of navigation elements, advertisements, and disclaimers.
Revenue per share of Penumbra, Inc. – HAN:0P8
This page provides financial data for Penumbra, Inc. (HAN:0P8) on the Hannover Stock Exchange, specifically focusing on its revenue per share. The article highlights the "Period," "Value," "Change," and "Change %" metrics for this financial indicator.
Penumbra stock breaks below 50-day average
Penumbra (ISIN US70975L1070) stock recently fell below its 50-day moving average, trading at USD 318.14 against an average of USD 321.74. This occurred despite the company reporting a 14.90% increase in second-quarter revenue to USD 390.05 million, surpassing analyst expectations. However, adjusted earnings per share missed estimates, coming in at USD 0.88 against a USD 1.16 consensus, indicating that while sales momentum is strong, earnings execution is a key concern for investors.
Average basic shares outstanding of Penumbra, Inc. – HAN:0P8
This article provides financial data for Penumbra, Inc. (HAN:0P8) traded on the Hannover Stock Exchange. It specifically focuses on the average basic shares outstanding, indicating a financial metric for the company. The page also lists various resources and sections related to market data and financial analysis tools.
Current ratio of Penumbra, Inc. – HAN:0P8
This article displays the current ratio for Penumbra, Inc. (HAN:0P8) on the TradingView platform. It shows that for the specified period, the value, change, and percentage change in the current ratio are not available, indicated as "No trades." The page provides financial information for the company listed on the Hannover Stock Exchange.
The Technical Signals Behind (PEN) That Institutions Follow
This article analyzes Penumbra Inc. (NYSE: PEN) using AI models, identifying a neutral near and mid-term outlook with a long-term positive bias. It highlights an exceptional risk-reward setup targeting a 7.9% gain, and presents specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Penumbra, Inc. (PEN) Stock Analysis: Evaluating A 13.93% Upside Potential
Penumbra, Inc. (PEN) is a medical devices company with a market cap of $12.51 billion, showing robust revenue growth and strong profitability. Analysts are cautiously optimistic, with an average target price suggesting a 13.93% upside potential. The company's strategic focus on innovation and expanding product offerings make it an intriguing opportunity for investors looking for capital appreciation in the healthcare sector.
Penumbra Inc. stock trades near 317 dollars as investors weigh growth and valuation
Penumbra Inc. stock is trading around USD 317.60, reflecting strong growth expectations and a notable double-digit performance over the past year. While current prices are about 10.6% above its modeled fair value of USD 283.93, suggesting a premium, the company's fundamentals and growth profile are seen to support this valuation. Investors are balancing this premium with the company's strong price momentum and its position in the large-cap healthcare segment.
Penumbra Inc. stock holds near 315 dollars as growth expectations stay high
Penumbra Inc. stock is trading around $315.79 on the New York Stock Exchange, reflecting strong growth expectations. The company reported a non-GAAP EPS of $3.63, up 36.47% year-on-year, with analysts projecting further EPS growth of 32.46% and revenue growth of 15.96% for the next year. A previous corporate action offered shareholders $374.00 per share or Boston Scientific shares, suggesting a potential upside from the current trading price.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
Penumbra, Inc. (PEN) is poised for growth due to its robust product portfolio expansion and successful international presence. However, the company faces operational risks from unfavorable foreign exchange rates and a rising expense base that outpaces revenue growth. Despite these challenges, its thrombectomy technology and international sales continue to be strong tailwinds.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
Penumbra, Inc. (PEN) is poised for growth due to its expanding product portfolio and international market penetration, despite potential headwinds from foreign exchange fluctuations and a rising expense base. The company's recent advancements in thrombectomy technology and FDA clearances are significant tailwinds, but increased operational costs and macroeconomic sensitivities present challenges.
Mechanical Clot Engagement Option for CAVT Thrombectomy Now Available
Penumbra has launched Link, a new clot capture device designed to enhance arterial thrombus removal when used with its Lightning Bolt technology. Link mechanically engages and holds clots, integrating with computer-assisted vacuum thrombectomy (CAVT) to improve clot extraction, especially in challenging cases. This advancement aims to provide physicians with more flexibility, improve procedural efficiency, and ultimately lead to more effective patient care.
Penumbra (BSP:P2NB34) Loans Receivable : R$0 Mil (As of Jun. 2026)
Penumbra (BSP:P2NB34) reported R$0 Mil in Loans Receivable as of June 2026. GuruFocus rates Penumbra with a GF Score™ of 21/100 and considers it "Fairly Valued" with a GF Value™ of R$56.70. The article highlights that the stock trades slightly below its estimated fair value and has one warning sign.
Penumbra Inc (BSP:P2NB34) Stock Earnings Transcripts
This page provides a comprehensive list of earnings call transcripts and conference transcripts for Penumbra Inc (BSP:P2NB34), a medical devices company. It includes transcripts from various quarterly earnings calls and presentations at healthcare conferences, dating back to 2018. The page also displays key financial metrics for Penumbra Inc.
Penumbra Inc Stock Operating Data
This GuruFocus.com article provides operating data for Penumbra Inc (BSP:P2NB34), including its stock price, P/E ratio, market capitalization, and enterprise value. It notes that operating data is not available for annual or quarterly periods. The article also highlights a medium warning sign detected by GuruFocus for the stock.
Penumbra Inc (BSP:P2NB34) Stock Price, Trades & News
This GuruFocus article provides a comprehensive overview of Penumbra Inc (BSP:P2NB34), including its stock price, trading information, and news. It details various financial metrics such as financial strength, growth, profitability, and valuation ratios, alongside business descriptions, executive information, and upcoming financial events. The article also lists warning signs detected by GuruFocus and answers frequently asked questions about the company's stock and dividends.
TFX or PEN: Which Is the Better Value Stock Right Now?
This article analyzes Teleflex (TFX) and Penumbra (PEN) to determine which is a better value stock within the Medical - Instruments sector. Using Zacks Rank and Style Scores, it concludes that TFX is the better option due to its #2 (Buy) Zacks Rank, stronger earnings outlook improvement, and more attractive valuation metrics like a lower P/E ratio, PEG ratio, and P/B ratio compared to PEN.
Incuvate Files Patent Infringement Lawsuit Against Penumbra
Incuvate, LLC has filed a patent infringement lawsuit against Penumbra, Inc. in the U.S. District Court for the Northern District of California. The lawsuit alleges that Penumbra’s THUNDERBOLT™ Neurovascular Thrombectomy System infringes five Incuvate patents related to real-time aspiration monitoring technology used in catheter-based thrombectomy procedures. Incuvate is seeking damages, injunctive relief, and other remedies for the alleged unauthorized and willful infringement.
Incuvate Files Patent Infringement Lawsuit Against Penumbra
Incuvate, LLC has filed a patent infringement lawsuit against Penumbra, Inc. in the U.S. District Court for the Northern District of California. Incuvate alleges that Penumbra's THUNDERBOLT™ Neurovascular Thrombectomy System infringes five of its patents related to real-time aspiration monitoring technology used in catheter-based thrombectomy procedures. Incuvate is seeking damages, injunctive relief, and other remedies.
Penumbra, Inc. (PEN) Stock Analysis: Exploring Growth Potential And Market Position
Penumbra, Inc. (PEN) is a prominent healthcare player with a $12.81 billion market cap, specializing in innovative medical devices like thrombectomy and embolization solutions. The company shows strong revenue growth of 14.90% and an 11.37% return on equity, backed by solid financials and a free cash flow of $161.1 million. While its valuation, including a high forward P/E, suggests a premium for future earnings, analyst ratings are cautiously optimistic, with an average target price indicating an 11.27% potential increase.
Penumbra Gets CE Mark for Thunderbolt Stroke Device in Europe
Penumbra has received CE Mark approval for its Thunderbolt device, which is designed to treat ischemic stroke. This approval allows the device to be marketed in Europe. Thunderbolt is a part of Penumbra's advanced neurovascular access portfolio, offering physicians a new tool for clot removal in stroke patients.
Trillium Asset Management LLC Acquires New Stake in Penumbra, Inc. $PEN
Trillium Asset Management LLC has acquired a new stake in Penumbra, Inc. (NYSE:PEN), purchasing 17,857 shares valued at approximately $5.64 million during the second quarter. Other institutional investors like BlackRock Inc. and Artisan Partners Limited Partnership also significantly increased their positions, bringing the total institutional ownership to 88.88% of Penumbra's outstanding shares. Despite the increased institutional interest, analysts maintain a "Hold" rating for Penumbra with an average price target of $367.07, as the company's latest quarterly EPS of $0.88 fell short of estimates, even though revenue grew by 14.9%.
Penumbra, Inc. (NYSE:PEN) Given Average Recommendation of "Hold" by Analysts
Analysts have issued a consensus "Hold" rating for Penumbra, Inc. (NYSE:PEN), with 13 out of 17 firms recommending hold, three recommending buy, and one recommending sell. The average 12-month price target is $367.07. Despite quarterly revenue of $390.05 million exceeding estimates, the company missed EPS forecasts, reporting $0.88 against a $1.16 consensus.
Penumbra (NYSE: PEN) grants president 3,060 RSUs with multi-year vesting
Penumbra Inc. (PEN) granted its President, Shruthi Narayan, 3,060 Restricted Stock Units (RSUs) on August 17, 2026, under the company's 2014 Equity Incentive Plan. These RSUs will vest in four equal annual tranches starting August 15, 2027, contingent on continued service, with an alternative vesting schedule if a specific merger agreement dated January 14, 2026, closes. Following this grant, the President beneficially owns 33,880 common shares, including 65 shares purchased through the Employee Stock Purchase Plan.
NINE MASTS CAPITAL Ltd Acquires New Position in Penumbra, Inc. $PEN
NINE MASTS CAPITAL Ltd recently acquired a new position in Penumbra, Inc. (NYSE:PEN), purchasing 23,264 shares valued at approximately $7.35 million in the second quarter. This investment makes Penumbra the 20th largest holding for NINE MASTS CAPITAL Ltd, representing about 0.06% of Penumbra and 0.7% of the fund's total holdings. Despite analysts maintaining a "Hold" rating and the company missing earnings per share estimates, institutional investors collectively own 88.88% of Penumbra.
Citizens Financial Group Inc. RI Invests $9.88 Million in Penumbra, Inc. $PEN
Citizens Financial Group Inc. RI has acquired a new stake of 31,286 shares in Penumbra, Inc. (NYSE:PEN) worth approximately $9.88 million during the second quarter. Other institutional investors also adjusted their holdings in Penumbra, with the company currently having 88.88% institutional ownership. Analysts have a consensus "Hold" rating for Penumbra with an average target price of $367.07, despite the company missing its Q2 earnings per share estimate.
Fidelity Advisor Mid Cap II Fund's Penumbra Inc(PEN) Holding History
This article details Fidelity Advisor Mid Cap II Fund's historical holdings in Penumbra Inc (PEN). As of March 31, 2026, the fund held no shares, having made three purchases and two sales of the stock since 2025Q1. Despite currently holding no shares, the fund realized an estimated gain of $3.04 million, or 25.33%, on its past PEN transactions.
Penumbra, Inc. (PEN) Stock Analysis: Exploring a 10.65% Potential Upside in the Healthcare Sector
Penumbra, Inc. (NYSE: PEN) is a leading medical device company with a $12.88 billion market capitalization, known for its thrombectomy systems and neurovascular products. The company shows strong revenue growth of 14.90% and a 11.37% Return on Equity, positioning it as an attractive investment despite not offering dividends. Analysts project a potential 10.65% upside with a consensus target price of $361.83, driven by its innovation and market expansion strategies.
Alberta Investment Management Corp Invests $10.46 Million in Penumbra, Inc. $PEN
Alberta Investment Management Corp recently acquired a new position in Penumbra, Inc. (NYSE:PEN), purchasing 33,120 shares valued at approximately $10.46 million. This investment comes as institutional investors and hedge funds now collectively own 88.88% of Penumbra, while analysts maintain a "Hold" consensus rating with an average price target of $367.07. Despite a 14.9% year-over-year revenue increase in its latest quarter, Penumbra's earnings per share of $0.88 missed the consensus estimate of $1.16.
Technical Reactions to PEN Trends in Macro Strategies
This article provides a technical analysis of Penumbra Inc. (NYSE: PEN), indicating neutral near and mid-term readings but a positive long-term bias. It highlights a 27.2:1 risk-reward setup targeting a 7.8% gain against 0.3% risk. The analysis includes institutional trading strategies for position trading, momentum breakouts, and risk hedging, along with multi-timeframe signal analysis.
Should Penumbra’s RED 68 Catheter Recall and Margin Strain Require Action From Penumbra (PEN) Investors?
Penumbra, Inc. recently initiated a voluntary Class II recall of its RED 68 Reperfusion Catheter due to manufacturing issues, which follows a quarter where the company reported higher sales but lower net income and reduced earnings per share. This article examines how the recall could impact Penumbra's growth and margin narrative, particularly in light of existing profitability pressures and investor expectations for long-term growth in stroke and vascular interventions. The recall highlights product quality and regulatory scrutiny as key risks to Penumbra's investment profile.
Should Penumbra’s RED 68 Catheter Recall and Margin Strain Require Action From Penumbra (PEN) Investors?
Penumbra, Inc. recently initiated a Class II recall of its RED 68 Reperfusion Catheter due to manufacturing issues, coinciding with a quarter reporting higher sales but lower net income and reduced earnings per share. This recall adds to existing margin pressures and raises concerns about product quality and regulatory scrutiny, potentially impacting the company's previously optimistic growth and profitability forecasts. Investors are advised to consider these developments as they could influence hospital trust and future device adoption, potentially reinforcing cautious analyst views on Penumbra's future performance.
Penumbra, Inc. (PEN) stock price, news, quote and history
This article provides a comprehensive overview of Penumbra, Inc. (PEN), a medical device company, including its current stock price, historical data, financial performance, and analyst insights. It details the company's product offerings in neurosurgical and peripheral thrombectomy devices and outlines key financial metrics and comparisons with other medical device companies. The report also highlights Penumbra's latest quarterly earnings and future growth estimates.
Should Penumbra’s RED 68 Catheter Recall and Margin Strain Require Action From Penumbra (PEN) Investors?
Penumbra, Inc. recently initiated a voluntary Class II recall of its Penumbra System RED 68 Reperfusion Catheter due to manufacturing issues, shortly after reporting higher quarterly sales but lower net income and reduced earnings per share. This recall adds to existing margin pressures and raises concerns about product quality and regulatory scrutiny, impacting Penumbra's growth narrative. Investors should consider these developments in light of the company's previously optimistic forecasts.
Penumbra, Inc. (PEN) Stock Analysis: Evaluating the 11.45% Potential Upside in Medical Devices
Penumbra, Inc. (NYSE: PEN), a medical devices company with a $12.79 billion market cap, shows a potential upside of 11.45% based on analyst target prices. Despite a premium valuation with a forward P/E of 52.95, the company exhibits strong performance with 14.90% revenue growth and robust free cash flow, reinvesting profits for innovation rather than paying dividends. Technical indicators suggest positive momentum, though the stock might be overbought, making it a compelling option for growth-oriented investors in the healthcare sector.
Bank of America Corp DE Sells 46,436 Shares of Penumbra, Inc. $PEN
Bank of America Corp DE reduced its stake in Penumbra, Inc. by 15.2% in the first quarter, selling 46,436 shares and retaining 259,775 shares valued at approximately $85.3 million. Despite Penumbra reporting a 14.9% year-over-year revenue increase to $390.05 million, its earnings per share of $0.88 missed analyst estimates of $1.16. The stock currently holds a consensus "Hold" rating from analysts with an average price target of $367.07.
Royal Bank of Canada Decreases Holdings in Penumbra, Inc. $PEN
Royal Bank of Canada significantly reduced its stake in Penumbra, Inc. by nearly 50% in the first quarter, selling 39,656 shares and retaining 39,794 shares valued at $13.1 million. This comes as Penumbra reported mixed financial results, with revenue slightly above estimates but EPS missing consensus. Analyst sentiment for Penumbra remains cautious, with a consensus "Hold" rating and an average price target of $367.07.
Penumbra Inc (PEN) Stock News Today
This article provides current stock information for Penumbra Inc (PEN), including its latest stock price, market capitalization, and P/E ratio. It notes that this page will feature news, earnings, analyst ratings, and key developments related to PEN stock, with more updates expected soon. The article is primarily a placeholder for future news and analysis on the company.
The Manufacturers Life Insurance Company Sells 65,658 Shares of Penumbra, Inc. $PEN
The Manufacturers Life Insurance Company significantly reduced its stake in Penumbra, Inc. by selling 65,658 shares, now holding 20,047 shares valued at $6.6 million. Despite collective institutional ownership of 88.88%, analyst sentiment for Penumbra is mixed with a "Hold" consensus and a target price of $367.07. Penumbra reported quarterly revenue of $390.05 million, exceeding estimates, but missed earnings per share forecasts with $0.88 against a $1.16 consensus.
Penumbra, Inc. (PEN) Stock Forecasts
This article provides a stock forecast for Penumbra, Inc. (PEN), a US-based company that designs and markets thrombectomy and embolization devices. The report highlights the company's focus on minimally invasive devices for hospitals and physicians. Access to the full report is exclusive to Yahoo Finance Silver subscribers.
THUNDER study demonstrates Penumbra's Thunderbolt CAVT system is safe and effective for stroke care
Penumbra, Inc. announced positive results from its THUNDER study, evaluating the safety and effectiveness of its Thunderbolt computer-assisted vacuum thrombectomy (CAVT) system for stroke patients with emergent large vessel occlusion (ELVO). The study showed high rates of successful reperfusion and complete clot ingestion with low complication rates, suggesting a significant advancement in stroke treatment options. The Thunderbolt system, which introduces modulated aspiration, recently received U.S. FDA clearance and CE Mark.
Trading the Move, Not the Narrative: (PEN) Edition
The article provides a detailed AI-driven analysis for Penumbra Inc. (NYSE: PEN), highlighting near-term strong sentiment transitioning to mid-term neutrality and long-term positive bias. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and specific support and resistance levels. The analysis emphasizes a significant risk-reward setup, targeting a 7.8% gain versus 0.3% risk.
Did Penumbra's (PEN) Voluntary RED 68 Catheter Recall Just Shift Its Investment Narrative?
Penumbra, Inc. recently initiated a voluntary Class II recall of its RED 68 Reperfusion Catheter due to manufacturing issues, raising questions about product quality and future regulatory scrutiny. This recall follows a Q2 2026 report showing higher sales but lower net income, suggesting operational risks could now outweigh growth prospects. Investors are advised to consider these new manufacturing concerns alongside Penumbra's long-term growth narrative in minimally invasive interventions.
Did Penumbra's (PEN) Voluntary RED 68 Catheter Recall Just Shift Its Investment Narrative?
Penumbra, Inc. recently initiated a voluntary Class II recall of its RED 68 Reperfusion Catheter due to manufacturing issues that may cause the device to fracture. This recall follows a quarter where the company reported higher sales but lower net income, raising concerns about product quality control and potential regulatory scrutiny. The article suggests this event could significantly influence Penumbra's investment narrative, challenging analyst forecasts and highlighting operational risks alongside growth opportunities.
Amundi Buys 259,936 Shares of Penumbra, Inc. $PEN
Amundi increased its stake in Penumbra, Inc. by 302.9% in the first quarter, purchasing 259,936 additional shares to hold a total of 345,758 shares valued at $113.5 million. Institutional investors now own 88.88% of the company. Despite Penumbra's recent quarterly revenue slightly exceeding estimates, its earnings per share missed the consensus forecast.
Penumbra Inc 2Q 2026: Revenue $390.05M, EPS $0.88— 10-Q Summary
Penumbra Inc (PEN) reported its second-quarter 2026 results, with revenue reaching $390.05 million, a 14.9% increase year-over-year. Despite revenue growth, net income and diluted EPS decreased to $34.81 million and $0.88, respectively, due to strategic investments. The company also announced a merger agreement to be acquired by Boston Scientific for approximately $14.5 billion.
Penumbra (NYSE: PEN) Q2 revenue reaches $390.0 million amid Boston Scientific deal
Penumbra Inc. reported Q2 2026 revenue of $390.0 million, a 14.9% increase year-over-year, driven by strong growth in thrombectomy and embolization products. The company will not provide full-year 2026 financial guidance or host a conference call due to its pending acquisition by Boston Scientific Corporation, which also led to $6.9 million in acquisition-related expenses during the quarter. Despite a net income of $34.8 million, this was lower than the previous year, with the company’s balance sheet showing increased cash and marketable investments.
Penumbra, Inc. Revenue Breakdown – NYSE:PEN
This article details Penumbra, Inc.'s (NYSE: PEN) revenue breakdown, highlighting that the company generated $1.40 billion USD last year. Its top-performing segment was Thrombectomy, contributing $947.92 million USD, and the United States was its largest regional contributor with $1.09 billion USD.
Press Release: Penumbra, Inc. Reports Second Quarter 2026 Financial Results
Penumbra, Inc. announced its financial results for the second quarter of 2026. The company reported significant revenue growth, driven by strong performance across its neuro and vascular businesses. This press release provides a detailed overview of their financial achievements and key operational highlights during the quarter.
